J&J Struggles to Sway Court Over Samsung Stelara Biosimilar Copy

Johnson & Johnson struggled Tuesday to convince a three-judge panel that the launch of a biosimilar to its psoriasis drug Stelara harms the company.

“Why isn’t a monetary damage sufficient?” Judge Cheryl Ann Krause for the US Court of Appeals for the Third Circuit asked an attorney for J&J in an oral argument.

Judge Arianna J. Freeman, who was appointed by former President Joe Biden, joined Krause’s skepticism and questioned the drugmaker’s claim that the biosimilar at issue harms the company’s market but that calculating that disruption is difficult.

“How do we decide how difficult is too difficult?” Freeman asked ...